Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2018-04-24 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
董事、监事及高级管理人员薪酬管理制度（2018年4月）
Remuneration Information Classification · 95% confidence The document is titled '董事、监事及高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors, Supervisors, and Senior Management'. It details the principles, management structure, composition, determination, and performance assessment of remuneration for company directors and senior management. It references the company's governance and remuneration policies, including the role of the board and committees in setting pay. There is no financial data or report of results, but rather a detailed policy document on executive compensation. This matches the definition of a Remuneration Information filing (DEF 14A). The document length is short and focused solely on remuneration policy, not an announcement or report publication. Therefore, the correct classification is DEF 14A with high confidence.
2018-04-24 Chinese
累积投票制实施细则（2018年4月）
Governance Information Classification · 95% confidence The document is titled as "累积投票制实施细则" which translates to "Cumulative Voting System Implementation Rules". It details the rules and procedures for cumulative voting in the election of directors and supervisors at the company. The content focuses on governance structure, nomination, voting, and election rules for board members and supervisors. There is no financial data, no mention of financial results, no audit information, no shareholder voting results, no announcements of meetings, or any other report type. The document is a governance-related internal rule or guideline document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 2869 characters, which is consistent with a detailed governance policy document rather than a brief announcement or a full annual report. Hence, the classification is CGR with high confidence.
2018-04-24 Chinese
信息披露管理制度（2018年4月）
Governance Information Classification · 100% confidence The document is titled '北京双鹭药业股份有限公司 信息披露管理制度' which translates to 'Beijing SL Pharmaceutical Co., Ltd. Information Disclosure Management System'. The content is a detailed internal policy document outlining the company's procedures, responsibilities, and standards for information disclosure, including definitions, reporting requirements, internal controls, confidentiality, communication with investors and regulators, and accountability. It references various regulatory frameworks such as the Company Law, Securities Law, Shenzhen Stock Exchange Listing Rules, and China Securities Regulatory Commission rules. The document does not contain any financial statements, earnings data, audit opinions, or specific event announcements. Instead, it is a governance and compliance manual for managing information disclosure. It is not a report, announcement, or filing of financial results or corporate actions. Therefore, the most appropriate classification is Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2018-04-24 Chinese
内幕信息知情人登记管理制度（2018年4月）
Governance Information Classification · 95% confidence The document is a detailed internal policy and procedural manual titled '内幕信息知情人登记管理制度' (Insider Information Insider Registration Management System) for Beijing Shuanglu Pharmaceutical Co., Ltd. It outlines the management, registration, confidentiality, and legal responsibilities related to insider information and insider persons. It includes definitions, scope, registration procedures, confidentiality agreements, and legal consequences for violations. There are no financial statements, earnings data, or investor presentations. It is not an announcement or a brief notice but a comprehensive governance and compliance document related to insider information management. This fits best under Governance Information (CGR), as it details internal rules, board structure, and governance practices related to insider information management.
2018-04-24 Chinese
董事会秘书工作制度（2018年4月）
Governance Information Classification · 100% confidence The document is a detailed internal governance policy titled 'Board Secretary Work System' for Beijing Shuanglu Pharmaceutical Co., Ltd. It outlines the roles, qualifications, responsibilities, appointment, and legal liabilities of the board secretary. It references relevant laws and stock exchange rules, and is clearly a governance-related document rather than a financial report or announcement. There is no financial data, no earnings or audit information, no voting results, no capital changes, or other report types. The content fits the definition of Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2018-04-24 Chinese
关于深圳证券交易所问询函回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. responding to an inquiry letter from the Shenzhen Stock Exchange regarding non-operating receivables from a related party. It discusses the formation, approval, and resolution of these receivables, internal control measures, and independence from related parties. The document is a regulatory response to an exchange inquiry, providing clarifications and disclosures about financial and operational matters but does not contain a full financial report, earnings release, or other formal report. It is not a certification letter, nor is it a brief announcement of a report publication. The document is a regulatory filing responding to a regulatory inquiry, fitting best under the category of Regulatory Filings (RNS). The document length is 4013 characters, which is relatively short and consistent with a regulatory announcement rather than a full report.
2018-04-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.